Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma

SIMPLE SUMMARY: Renal medullary carcinoma (RMC) is a rare and highly aggressive renal cell carcinoma, with a median survival of 13 months. Platinum-based chemotherapy is the recommended standard of care for RMC, but no effective salvage regimens have been established to date. Previous comprehensive...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiele, Andrew J., Surasi, Devaki Shilpa, Rao, Priya, Sircar, Kanishka, Su, Xiaoping, Bathala, Tharakeswara K., Shah, Amishi Y., Jonasch, Eric, Cataldo, Vince D., Genovese, Giannicola, Karam, Jose A., Wood, Christopher G., Tannir, Nizar M., Msaouel, Pavlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124338/
https://www.ncbi.nlm.nih.gov/pubmed/33946504
http://dx.doi.org/10.3390/cancers13092170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124338/
https://www.ncbi.nlm.nih.gov/pubmed/33946504
http://dx.doi.org/10.3390/cancers13092170

Ejemplares similares